4501 X St.
Sacramento, CA 95817
Ph.D., University of Illinois at Chicago, Chicago, Illinois, 1983
B.S., Loyola University, Chicago, Illinois, 1977
American Board of Internal Medicine, 2002
American Board of Internal Medicine, Medical Oncology, 1994
American Board of Internal Medicine, Medical Oncology, 2002
Honors and Awards:
U.S. Patent 6,217,871 "Antigenic Epitopes with Lym-1 Reactivity and Uses Thereof": Larry Rose, PhD, Claude Meares, PhD and Robert o"Donnell MD, PhD, 2001
American Cancer Society Clinical Fellowship, 1990
University of Illinois Graduate College Fellowship, 1983
Select Recent Publications:
Tuscano JM, YP Ma, SM Martin, J Kato, RT O'Donnell. The Bs20x22 Anti-CD20-CD22 Bispecific Antibody has more Lymphomacidal Activity than do the Parent Monoclonal Antibodies Alone.. Cancer Immunol. Immunother., 60: 771-780.
Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model. Clin Cancer Res, 16(10): 2760-8.
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-Hodgkin's lymphoma cells. Leuk Res. Feb 21. [Epub ahead of print]
2009 O'Donnell RT, D Pearson, HC McKnight, YP Ma, JM Tuscano. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy. Cancer Immunol Immunother. Mar 18. [Epub ahead of print]
2009 O'Donnell RT, SM Martin, YP Ma, WC Zamboni, JM Tuscano. Development and characterization of CD22-targeted pegylated liposomal doxorubicin (IL-PLD). Invest New Drugs. In press.
2009 O'Donnell RT, YP Ma, HC McKnight, D Pearson, JM Tuscano. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts. Cancer Immunol lmmunother. 58(12):2051-2058.
2008 Pearson DP, RT O'Donnell, K Lam, JM Tuscano. CD22-binding peptides derived from anti-CD22 ligand blocking antibodies retain the targeting and cell killing properties of the parent antibodies and may serve as a drug delivery vehicle. International Journal of Peptide Research and Therapeutics, 14:237-246.
2009 Martin SM, RT O'Donnell, DL Kukis, C Abbey, H McKnight, JL Sutcliffe, JM Tuscano. Imaging and pharmacokinetics of 64Cu-DOTA-HB22.7 administered by intravenous, intraperitoneal, or subcutaneous injection to mice bearing non-Hodgkin lymphoma xenografts. Mol Imaging BioI. 11(2):79-87.
2007 Schillaci O, GL DeNardo, SJ DeNardo, DS Goldstein, LA Kroger, RT O'Donnell, KR Lamborn. Effect of anti-lymphoma antibody, 131 I-Lym-1 on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm, 22(4):521-30.
2007 Semrad TJ, RT O'Donnell, T Wun, H Chew, D Harvey, H Zhou, RH White. Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg 106(4):601-608.
2006 Lehmann J, GL DeNardo, A Yuan, S Shen, RT O'Donnell, CM Richman, SJ DeNardo. Comparison of normal tissue pharmacokinetics with 1111n/90y monoclonal antibody m170 for breast and prostate cancer. Int J Radiat Oncol Biol Phys. 66(4):1192-1198.
2006 O'Donnell RT. Nuclear Localizing Sequences May be a New Way to Increase Efficacy and Decrease the Toxicity of Systemic Targeted Radiotherapy. Invited Perspective. Journal of Nuclear Medicine. 47(5):738-739.